Skip to content 
On August 28, 2023, the China Food and Drug Administration announced that Shanxi Jinbo Biomedical Co., Ltd.’s “recombinant type III humanized collagen solution for injection” was approved for listing.
This product is a colorless or off-white liquid, composed of recombinant type III humanized collagen and 0.9% saline, suitable for facial dermal tissue filling to correct forehead dynamic wrinkles (including glabellar lines, forehead lines and crow’s feet) . The recombined collagen biomaterial used in this product can be assembled into a collagen fiber network, which supports cells and tissues, and physically fills the collapsed parts of wrinkles. The risk of immunogenicity of the product is controllable, and it will be gradually decomposed and absorbed by collagenase in the body after injection.
The recombinant type III humanized collagen used in it was jointly developed by Jinbo Biotechnology, Fudan University, Institute of Biophysics, Chinese Academy of Sciences, Sichuan University, and the Second Affiliated Hospital of Chongqing Medical University. The material has a precise and stable 164.88°flexible triple helix structure, strong water solubility, higher activity than the human body’s own collagen, and has the same amino acid sequence as the core functional area of human collagen, no risk of immunogenicity and virus contamination, high safety, and can be widely used in clinical skin, bone , cartilage, cardiovascular system, oral cavity and luminal tissue repair and regeneration, as well as beauty cosmetics and other fields.
